Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH
Top

15-06-2019 | Rheumatoid arthritis | EULAR 2019 | Article

Researcher comment: The FINCH 3 trial

print
PRINT
insite
SEARCH

Rene Westhovens summarizes the results of the FINCH 3 trial, which investigated filgotinib with and without methotrexate in rheumatoid arthritis patients with no prior methotrexate exposure (3:40).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

print
PRINT

Related content

14-06-2019 | Rheumatoid arthritis | EULAR 2019 | Article

Expert commentary: The FINCH 1 and FINCH 3 trials

15-06-2019 | Rheumatoid arthritis | EULAR 2019 | Article

Expert commentary: The FINCH 3 trial

17-06-2019 | Rheumatoid arthritis | EULAR 2019 | News

Filgotinib beneficial for RA patients with no prior methotrexate exposure

29-03-2019 | Rheumatoid arthritis | Feature | Article

JAK inhibitors in RA: A round-up of the phase 3 trials
Image Credits